Planning Committee:

Laura A. Magee, MD, FRCPC, MSc, FACP
Anne Synnes, MDCM, MHSc, FRCPC
Diane Sawchuck, RN, PhD
Robert Liston, MB, ChB, FRCOG, FRCSC, FACOG
Peter von Dadeslzen, MBChB, DPhil, FRCSC

Learning Objectives:

1. Review the evidence for the use of antenatal magnesium sulphate for fetal neuroprotection of the preterm infant

2. Understand the benefits, risks, and costs of magnesium sulphate treatment for mothers and babies

3. Understand the indications for, and dosage and duration of, treatment with magnesium sulphate for fetal neuroprotection

4. Understand how to monitor women and their fetuses when administering magnesium sulphate for fetal neuroprotection

5. Understand the potential barriers to implementing protocols for magnesium sulphate administration and how to overcome them

6. Review resources available for maternity care providers administering magnesium sulphate for fetal neuroprotection to women with ‘imminent’ preterm birth

Page 1 of 2

Loading... Loading...
You have selected an option that triggers this survey to end right now. To save your responses and end the survey, click the button below to do so. If you have selected the wrong option by accident and do not wish to leave the survey, you may click the other button below to continue, which will also remove the value of the option you just selected to allow you to enter it again and continue the survey.
The response has now been removed for the last question for which you selected a value. You may now enter a new response for that question and continue the survey.